Nucleome Therapeutics Appoints Dr. Michelle Morrow as Chief Scientific Officer
Nucleome Therapeutics CSO appointment marks a significant leadership milestone as Nucleome Therapeutics names Dr. Michelle Morrow as its new Chief Scientific Officer, effective 23 February 2026. The appointment strengthens...

